Patients living with dementia utilize emergency departments (ED), hospitals, and skilled nursing facilities 2-3 times more frequently than those without the condition. Many of these facility admissions are avoidable.
The First Digital Engagement Platform Designed Specifically to Empower Family Caregivers of Patients Living with Dementia or Cognitive Impairment.
Purpose-built Digital Platform delivers content, workflows, assessments and messaging on a Ceresti Health Station, i.e., a tablet optimized for seniors, a mobile App or a web portal.
Health Information & Tools
Our extensive library of evidence-based Health Information & Tools complements and enhances existing patient engagement content.
We maximize caregiver and patient engagement as a result of continuous and adaptive program personalization. Personalization is informed by predictive analytics that are founded in caregiver beliefs, competencies, preferences and patient needs.
Ceresti Coaches help family caregivers understand their loved one’s health challenges, and motivate a proactive approach in managing their loved one’s health.
Dirk Soenksen is a strategic results-oriented healthcare executive with over 25 years experience. Prior to Ceresti, Mr. Soenksen founded venture-backed Aperio and served in the positions of President/CEO/Chairman until its acquisition by Danaher/Leica Biosystems in 2012. He built a winning team that established Aperio as the recognized global leader in digital pathology, with a staff of 200, a rich portfolio of patents, healthy and growing revenue, multiple FDA clearances, and an installed base of more than 1,000 systems in 35 countries. He earned his AB degree in Chemistry from Bowdoin College, MSEE from the University of Pennsylvania, and his MBA from Pepperdine University.
Kevin Liang, PhD is trained as a neuroscientist and has 15 years experience in clinical study design/management, and regulatory affairs. Before co-founding Ceresti, Dr. Liang was founder and Managing Director of Milestone Research, a boutique medical device consultancy. Prior to Milestone, Dr. Liang was responsible for clinical affairs at Aperio. He earned his doctorate from the University of California, Irvine and is the author of numerous peer-reviewed articles, FDA research protocols and technical publications.
Mark Wrenn has over 30 years experience developing reliable and scalable software architectures. Before co-founding Ceresti, Mr. Wrenn was Sr. Director of Product and Business Development at Aperio where he led the development of a global, HIPAA compliant, cloud-based second opinion network for pathology. He also served as Director of Professional Services where he delivered value-added software and services, including interfaces to third-party IT systems, for a pathology PACS. He earned his BSEng in Computer Science from the University of Connecticut.
Chris Selecky has more than 30 years of experience in managed care and population health management and is Chair of the Board of the Population Health Alliance, the national trade association of the Population Health industry. She is an innovative and accomplished chief executive and entrepreneur in the healthcare industry including co-founding and growing a market leading disease management company from start-up to $130 million in revenues and leading a $2 billion business unit of a publicly traded managed care organization.
She serves on for-profit boards of directors and provides strategic consulting and advice to management teams and investors currently in or seeking to enter the healthcare field. Her areas of expertise include population health management, wellness and prevention, care coordination, disease management, commercial and Medicare managed care, and delivery system management.
Dr. Norman has 30 years of experience in population health, value-based care, and provider transformation. His career has focused on supporting provider & health systems, ACOs, and health plans as they pivot to the value-based care era where cost efficiency, quality outcomes, and experience of care are balanced to formulate the overall value of health care delivery.
Most recently, Dr. Norman led the Health System Consulting practice at Willis Towers Watson where he worked directly with health systems transitioning to value-based care. Previously, he served as Chief Medical Officer for xG Health Solutions, where he adapted and disseminated the value-based care know-how and tools developed by Geisinger Health System for other delivery systems transforming from fee-for-volume to fee-for-value care models. Before that, he held a series of executive leadership roles in multiple sectors of the healthcare ecosystem, with a consistent focus on population health management and value improvement.
Rob Lonardo has more than 35 years of experience in managed care with an emphasis on Medicare Advantage, Dual Eligibles and SPD (Seniors and Persons with Disabilities) populations. Rob’s career has included leadership roles at FHP Healthcare, Blue Shield of California and running a large IPA serving the Inland Empire and San Diego markets. Rob led CareMore Medical Enterprises for nearly 6 years, initially working for its physician owners, and subsequently running Growth and Business Development after Anthem’s acquisition of CareMore. Most recently, he worked at Alignment Healthcare in Orange, CA serving in multiple leadership roles.
Rob has a true passion for changing the way care is delivered, particularly to seniors. He has been a leader in improved coordination of care, better use of technology, using data to help health plans ‘find’ the patients that need them most, and assuring that every member with any disease or condition gets the care they need when and where it should be delivered.
While we are squarely focused on improving patient care and reducing healthcare costs, our broader mission is to change the conversation around dementia. We believe there is a compelling opportunity to align Ceresti’s solutions with national initiatives aimed at finding a cure for Alzheimer’s Disease. For example, our family caregiver empowerment programs can potentially reduce U.S. healthcare costs by hundreds of billions of dollars over the course of a decade. Redirecting these savings to finding a cure could result in a more than 10-fold increase over current funding levels.
We also believe that our solutions could be deployed with new or existing treatment agents to enable new treatments for Alzheimer’s Disease, a disease area that has seen no new drug approvals since 2003.